Amgen and Astellas join forces in Japan
California-based biotechnology company Amgen has entered into a long-term partnership with Japanese pharmaceutical company Astellas Pharmas Inc to provide new medicines in Japan.
Patents covering IVF test spark row
Members of the scientific community have blasted Stanford University and US biotechnology company Auxogyn for their involvement in patenting a test designed to increase the success of in vitro fertilisation (IVF).
Hi-tech and life sciences dominate at EPO awards
The inventor of the world’s first flat-panel liquid crystal display, Martin Schadt, was among a number of winners at the European Patent Office European Inventor Award 2013.
WHO issues IP warning over MERS virus
The World Health Organization has warned that “no IP will stand in the way of public health actions” amid the spreading of a deadly global virus.
Actavis to buy Warner Chilcott
Actavis announced on May 20 it will acquire specialty pharmaceutical company Warner Chilcott plc in a deal worth an estimated $5 billion.
Supreme Court to hear Medtronic case
The US Supreme Court has agreed to hear a patent infringement case between medical device manufacturers Medtronic and Boston Scientific.
RuiYi joins with Genor to develop cancer treatment
San Diego-Shanghai biotechnology startup RuiYi Inc has entered into an exclusive license and collaborative development agreement with Shanghai-based Genor BioPharma to develop the RYI-008 molecule in China.
Ideas Matter: the importance of IP in the fight against cancer
On May 14, healthcare experts met in London to share and discuss developments in cancer detection, prevention, treatment and maintenance, and how IP protection and management are vital in attracting investment.
Ideas Matter: Philips and Microsoft in life sciences
At the Ideas Matter roundtable last week LSIPR spoke to Maaike van Velzen, general manager of Philips Group Innovation’s IP and Standards division, about the importance of using IP to promote the company’s vision.
IP key to US biosimilars success – report
Strong IP knowledge is one of four key factors to succeeding in the burgeoning US biosimilars market, according to an industry report.
